Turning Point Therapeutics Inc. (TPTX) – Globe Newswire
-
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
-
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
-
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
-
TURNING POINT THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TPTX and Encourages Investors to Contact the Firm
-
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
-
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
-
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates
-
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
-
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
-
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
-
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
-
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
-
Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology Company
-
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
-
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update
-
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference
-
Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates
-
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
-
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cance
-
Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones
-
Syneos Health Appoints Two New Independent Directors
-
Turning Point Therapeutics Provides Regulatory Updates
-
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
-
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
-
Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations
-
Turning Point Therapeutics to Host Third Quarter 2021 Conference Call
-
Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
-
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Ca
-
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
-
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
-
Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates
-
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
-
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
-
Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference
-
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conferenc
-
Turning Point Therapeutics to Participate In Upcoming Investor Conferences
-
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors
-
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
-
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
-
Turning Point Therapeutics to Host Second Quarter 2021 Conference Call
-
Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer
-
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
-
Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference
-
Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference
-
Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors
-
Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors
-
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
Back to TPTX Stock Lookup
